Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache

Overview of attention for article published in The Journal of Headache and Pain, October 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 16 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,388 followers.

RT @EHF_Official: #Galcanezumab 240mg proved effective and #safety in the management of episodic #cluster #headache (CH) either alone or ad…

23 Oct 2022

Reply Repost Favourite

RT @EHF_Official: #Galcanezumab 240mg proved effective and #safety in the management of episodic #cluster #headache (CH) either alone or ad…

20 Oct 2022

Reply Repost Favourite

#Galcanezumab 240mg proved effective and #safety in the management of episodic #cluster #headache (CH) either alone or added-on conventional #treatments. 78.8% patients had 50% or higher reduction in weekly #CH attacks at week 3 from baseline! Read more:

20 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.